🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

8 recruiting trials

for Non-Proliferative Diabetic Retinopathy

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy NCT06662994Phase 41 site📍 Fullerton Retina Consultants of Orange County · Tests: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy NCT06817265Phase 330 sites📍 Xuancheng📍 Beijing📍 Guangzhou Beletalent (Zhuhai) Pharmaceutical Co., Ltd · Tests: TNTL, TNTL simulation preparation A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy NCT07235085Phase 31 site📍 Hagerstown Ocular Therapeutix, Inc. · Tests: Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, In… Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema NCT07592273Phase 2, Phase 338 sites📍 Mesa📍 Phoenix📍 Scottsdale AbbVie · Tests: Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy. NCT06701721Phase 110 sites📍 Parramatta📍 Sydney📍 Westmead Therini Bio Pty Ltd · Tests: THN391 Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion NCT07259928Phase 21 site📍 London Annexin Pharmaceuticals AB · Tests: ANXV Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy NCT06713720NA2 sites📍 Beijing📍 Beijing Xuxiang Zhang, MD · Tests: Remote Ischemic Conditioning Device, Sham Remote Ischemic Conditioning Device A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy NCT06321302Phase 290 sites📍 Phoenix📍 Bakersfield📍 Beverly Hills Boehringer Ingelheim · Tests: BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy